Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.53 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27158539 | 0.88 | KMT2A (0.55) | HPGDLMNAMRGPRX4SMN1; SMN2MAPT | |
| SCHEMBL2809626 | 0.87 | MRGPRX4 (0.51) | HPGDLMNAMRGPRX4SMN1; SMN2MAPT | |
| SCHEMBL25721332 | 0.86 | HPGD (0.54) | HPGDLMNAMRGPRX4SMPD1HDAC1 | |
| SCHEMBL2173086 | 0.86 | LMNA (0.54) | HPGDLMNAMRGPRX4SMPD1HDAC1 | |
| SCHEMBL30696120 | 0.86 | MRGPRX4 (0.66) | HPGDMRGPRX4SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL6959477 | 0.86 | MRGPRX4 (0.66) | HPGDMRGPRX4SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL16447278 | 0.85 | HPGD (0.65) | HPGDLMNAMRGPRX4SMPD1HDAC1 | |
| SCHEMBL2831563 | 0.83 | HPGD (0.43) | HPGDLMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL17318725 | 0.83 | LMNA (0.56) | HPGDLMNAMRGPRX4SMPD1HDAC1 | |
| SCHEMBL16015342 | 0.83 | LMNA (0.67) | HPGDLMNAMRGPRX4SMPD1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633738-A1 | CYTOTOXIC COMPOUNDS | Pheon Therapeutics Ltd (GB) | 2025-10-22 | — | — | EP | disclosed |
| EP-3932909-B1 | BENZOINDAZOLONE COMPOUND, AND INTERMEDIATE THEREOF | LMITO THERAPEUTICS INC (KR) | 2025-04-02 | — | — | EP | disclosed |
| US-12187683-B2 | Benzoindazolone compound and intermediate thereof | LMITO THERAPEUTICS INC. (KR) | 2025-01-07 | — | — | US | disclosed |
| CN-113454068-B | Benzonazolone compounds and intermediates thereof | LMITO药业株式会社 | 2024-08-02 | — | — | CN | disclosed |
| WO-2024127332-A1 | CYTOTOXIC COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-06-20 | — | — | WO | disclosed |
| US-20240002379-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-01-04 | — | — | US | disclosed |
| US-20230302142-A1 | Cytotoxic Agents | Pheon Therapeutics Ltd. (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230302142-A1 | Cytotoxic Agents | Pheon Therapeutics Ltd. (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20220144780-A1 | BENZOINDAZOLONE COMPOUND AND INTERMEDIATE THEREOF | LMITO THERAPEUTICS INC. (KR) | 2022-05-12 | — | — | US | disclosed |
| US-20220098191-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | Pheon Therapeutics Ltd. (GB) | 2022-03-31 | — | — | US | disclosed |
| EP-3932909-A1 | BENZOINDAZOLONE COMPOUND, AND INTERMEDIATE THEREOF | Lmito Therapeutics Inc. (KR) | 2022-01-05 | — | — | EP | disclosed |
| EP-3917924-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | Femtogenix Limited (GB) | 2021-12-08 | — | — | EP | disclosed |
| CN-113454068-A | Benzoindazolone compounds and intermediates thereof | LMITO药业株式会社 | 2021-09-28 | — | — | CN | disclosed |
| WO-2020157491-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | FEMTOGENIX LIMITED (GB) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020157491-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | FEMTOGENIX LIMITED (GB) | 2020-08-06 | — | — | WO | disclosed |
| US-20190144443-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2019-05-16 | — | — | US | disclosed |
| US-20190144443-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187683-B2 | Benzoindazolone compound and intermediate thereof | NQO1, KEAP1, SQOR | HPGD 13/4885LMNA 1476/4885MRGPRX4 4126/4885 |
| US-20220098191-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | CCNA1, GNA15, RPS26 | HPGD 2486/4885LMNA 945/4885MRGPRX4 722/4885 |
| US-20220144780-A1 | BENZOINDAZOLONE COMPOUND AND INTERMEDIATE THEREOF | NQO1, KEAP1, SQOR | HPGD 13/4885LMNA 1476/4885MRGPRX4 4126/4885 |
| US-20240002379-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | TUBA1C, MTX2, CCNO | HPGD 4687/4885LMNA 1295/4885MRGPRX4 863/4885 |
| US-20190144443-A1 | ASYMMETRIC CONJUGATE COMPOUNDS | TUBA1C, MTX2, CCNO | HPGD 4691/4885LMNA 1295/4885MRGPRX4 784/4885 |
| US-20230302142-A1 | Cytotoxic Agents | ANXA11, ANXA5, HAX1 | HPGD 4473/4885LMNA 1518/4885MRGPRX4 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.